- •The role for DPP-4 in type 1 diabetes is still not clarified.
- •Serum DPP-4 activity was evaluated in young-adult type 1 diabetes patients.
- •DPP-4 activity was significantly elevated in type 1 diabetes compared to controls.
- •DPP-4 activity was correlated with duration of diabetes and GGT level, but not HbA1c.
- •The results suggest a potential implication of DPP-4 in type 1 diabetes.
Currently, inhibition of dipeptidyl peptidase-4 (DPP-4) is widely used in the treatment of type 2 diabetes. Application of this strategy is awaited as a new therapeutic approach for type 1 diabetes, but the scientific basis is still lacking. This report describes the evaluation of serum DPP-4 activity in type 1 diabetes compared with control subjects, and assessment of relationships between DPP-4 activity and diabetic complication markers and metabolic variables in type 1 diabetes.
We examined serum DPP-4 activity in Japanese young-adult type 1 diabetes (n = 76, females 69.7%, age 30.9 ± 6.2 years, duration of diabetes 16.5 ± 11.1 years; mean ± SD) and healthy controls (n = 22). Association of the enzymatic activity with diabetic micro- and macro- vascular complication markers and clinical parameters was also assessed.
Subjects with type 1 diabetes displayed significantly higher serum DPP-4 activity than healthy controls (relative value, control: 1.00 ± 0.28, T1D, 1.29 ± 0.38; p = 0.0011) independent of other clinical parameters. In type 1 diabetes, DPP-4 activity was positively correlated with duration of diabetes (r = 0.248, p = 0.031), while not correlated with HbA1c level. In univariate correlation analysis of diabetic complication markers and other metabolic parameters, coefficient of variation of R-R intervals (CVR-R) and gamma (γ)-glutamyltransferase (GGT) levels were correlated with DPP-4 activity. GGT was extracted as an independent variable of DPP-4 activity in multivariate analysis (β = 0.213, p = 0.035).
Serum DPP-4 activity is significantly elevated in Japanese type 1 diabetes, suggesting pathophysiological significance of the enzyme in type 1 diabetes.
To read this article in full you will need to make a payment
Purchase one-time access:Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
One-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:Subscribe to Diabetes Research and Clinical Practice
Already a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
- Dipeptidyl peptidase-4 inhibition and the treatment of type 2 diabetes: preclinical biology and mechanisms of action.Diabetes Care. 2007; 30: 1335-1343
- Dipeptidyl peptidase-4: a key player in chronic liver disease.World J Gastroenterol. 2013; 19: 2298-2306
- Dipeptidyl peptidase 4 is a novel adipokine potentially linking obesity to the metabolic syndrome.Diabetes. 2011; 60: 1917-1925
- Dipeptidyl peptidase-4 inhibitors for treatment of type 2 diabetes mellitus in the clinical setting: systematic review and meta-analysis.BMJ. 2012; 344: e1369
- The effects of dipeptidyl peptidase-4 inhibition on microvascular diabetes complications.Diabetes Care. 2014; 37: 2884-2894
- Effect of sitagliptin on glucose control in adult patients with type 1 diabetes: a pilot, double-blind, randomized, crossover trial.Diabet Med. 2011; 28: 1176-1181
- Plasma dipeptidyl peptidase-IV activity in patients with type-2 diabetes mellitus correlates positively with HbAlc levels, but is not acutely affected by food intake.Eur J Endocrinol. 2006; 155: 485-493
- The increased dipeptidyl peptidase-4 activity is not counteracted by optimized glucose control in type 2 diabetes, but is lower in metformin-treated patients.Diabetes Obes Metab. 2012; 14: 518-522
- Higher serum DPP-4 enzyme activity and decreased lymphocyte CD26 expression in type 1 diabetes.Pathol Oncol Res. 2011; 17: 925-930
- Serum dipeptidyl peptidase 4 activity in children with type 1 diabetes mellitus.J Pediatr Endocrinol Metab. 2013; 26: 1093-1097
- Hyperglycaemia increases dipeptidyl peptidase IV activity in diabetes mellitus.Diabetologia. 2005; 48: 1168-1172
- Circulating dipeptidyl peptidase-4 activity is associated with diabetic retinopathy in type 1 diabetic patients.Eur J Ophthalmol. 2015; 25: 328-332
- Prevalence of carotid atherosclerosis in diabetic patients. Ultrasound high-resolution B-mode imaging on carotid arteries.Diabetes Care. 1992; 15: 1290-1294
- Validity, reproducibility, and clinical significance of noninvasive brachial-ankle pulse wave velocity measurement.Hypertens Res. 2002; 25: 359-364
- Cardiovascular effects of DPP-4 inhibition: beyond GLP-1.Vascul Pharmacol. 2011; 55: 10-16
- Skin collagen glycation, glycoxidation, and crosslinking are lower in subjects with long-term intensive versus conventional therapy of type 1 diabetes: relevance of glycated collagen products versus HbA1c as markers of diabetic complications.Diabetes. 1999; 48: 870-880
- Advanced glycation end products evoke endothelial cell damage by stimulating soluble dipeptidyl peptidase-4 production and its interaction with mannose 6-phosphate/insulin-like growth factor II receptor.Cardiovasc Diabetol. 2013; 12: 125
- The glucagonostatic and insulinotropic effects of glucagon-like peptide 1 contribute equally to its glucose-lowering action.Diabetes. 2010; 59: 1765-1770
- Molecular pathways underlying the pathogenesis of pancreatic alpha-cell dysfunction.Adv Exp Med Biol. 2010; 654: 421-445
- Dipeptidyl peptidase-IV expression and activity in human glomerular endothelial cells.Biochem Biophys Res Commun. 2003; 310: 28-31
- Increased hepatic expression of dipeptidyl peptidase-4 in non-alcoholic fatty liver disease and its association with insulin resistance and glucose metabolism.Mol Med Rep. 2012; 5: 729-733
- Advanced glycation end products (AGEs) and diabetic vascular complications.Curr Diabetes Rev. 2005; 1: 93-106
- Serum levels of advanced glycation end products (AGEs) are independently correlated with circulating levels of dipeptidyl peptidase-4 (DPP-4) in humans.Clin Biochem. 2013; 46: 300-303
- Adipose Dipeptidyl Peptidase-4 and Obesity: Correlation with insulin resistance and depot-specific release from adipose tissue in vivo and in vitro.Diabetes Care. 2013; 36: 4083-4090
- Revisiting an old acquaintance: CD26 and its molecular mechanisms in T cell function.Trends Immunol. 2008; 29: 295-301
- Interleukin-12 enhances CD26 expression and dipeptidyl peptidase IV function on human activated lymphocytes.Immunobiology. 1997; 197: 522-533
- Enhanced ovalbumin-induced airway inflammation in CD26−/− mice.Eur J Immunol. 2012; 42: 533-540
- Human Th17 cells express high levels of enzymatically active dipeptidylpeptidase IV (CD26).Eur J Immunol. 2012; 188: 5438-5447
- The new insights from DPP-4 inhibitors: their potential immune modulatory function in autoimmune diabetes.Diabetes Metab Res Rev. 2014; 30: 646-653
- Dipeptidyl peptidase IV (DDP IV) in NASH patients.Ann Hepatol. 2007; 6: 242-250
- Circulating dipeptidyl peptidase-4 activity correlates with measures of hepatocyte apoptosis and fibrosis in non-alcoholic fatty liver disease in type 2 diabetes mellitus and obesity: a dual cohort cross-sectional study.J Diabetes. 2014; https://doi.org/10.1111/1753-0407.12237
- Serum dipeptidyl peptidase-4 activity in insulin resistant patients with non-alcoholic fatty liver disease: a novel liver disease biomarker.PLoS ONE. 2010; 5: e12226
- Prevalence of non-alcoholic fatty liver disease and its association with cardiovascular disease in patients with type 1 diabetes.J Hepatol. 2010; 53: 713-718
Published online: January 14, 2016
Accepted: December 26, 2015
Received in revised form: December 16, 2015
Received: October 9, 2015
© 2016 Elsevier Ireland Ltd. Published by Elsevier Inc. All rights reserved.